Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)

of the IXORA-P Investigators

doi:10.1111/bjd.16426

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)

of the IXORA-P Investigators

Inernational Relations Division

Research output: Contribution to journal › Article › peer-review

46 Citations (Scopus)

Original language	English
Pages (from-to)	1315-1323
Number of pages	9
Journal	British Journal of Dermatology
Volume	178
Issue number	6
DOIs	https://doi.org/10.1111/bjd.16426
Publication status	Published - Jun 2018

ASJC Scopus Subject Areas

Dermatology

Access to Document

10.1111/bjd.16426

Cite this

@article{911cfa34e9724217b13d2ac86c38e48e,

title = "Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)",

author = "{of the IXORA-P Investigators} and Langley, {R. G.} and K. Papp and M. Gooderham and L. Zhang and C. Mallinckrodt and N. Agada and A. Blauvelt and P. Foley and P. Polzer",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.",

year = "2018",

month = jun,

doi = "10.1111/bjd.16426",

language = "English",

volume = "178",

pages = "1315--1323",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)

AU - of the IXORA-P Investigators

AU - Langley, R. G.

AU - Papp, K.

AU - Gooderham, M.

AU - Zhang, L.

AU - Mallinckrodt, C.

AU - Agada, N.

AU - Blauvelt, A.

AU - Foley, P.

AU - Polzer, P.

PY - 2018/6

Y1 - 2018/6

UR - http://www.scopus.com/inward/record.url?scp=85047448131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047448131&partnerID=8YFLogxK

U2 - 10.1111/bjd.16426

DO - 10.1111/bjd.16426

M3 - Article

C2 - 29405255

AN - SCOPUS:85047448131

SN - 0007-0963

VL - 178

SP - 1315

EP - 1323

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 6

ER -

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this